Nasus Pharma Ltd Research and Development Expense
Nasus Pharma Ltd (NSRX) reported Research and Development Expense of $2.24 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-25
| Period end | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|
| 2025-12-31 | $2.24M 20-F · filed 2026-03-25 | |
| 2025-06-30 | $289.00K 6-K · filed 2025-12-29 | |
| 2024-12-31 | $335.00K 20-F · filed 2026-03-25 | |
| 2024-06-30 | $168.00K 6-K · filed 2025-12-29 | |
| 2023-12-31 | $567.00K 20-F · filed 2026-03-25 |